◼ Archived
Business
🔮 fades
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping plans for an eczema drug derived from its billion-dollar Kymab acquisition following a strategic pipeline review.